[Rehabilitation program in patients with moderate-to-severe intermittent claudication: immediate results and one year follow-up].
BACKGROUND
Physical training is believed the primary treatment of claudication symptoms. Although exercise therapy is self-effective, some drugs improving functional capacity have additive effects. TASC (Trans Atlantic Society Consensus) considers Propionil-L-Carnitine (PLC) and prostaglandin-E1 (PGE1) as poorly studied drugs with potential benefits in improving claudication. This retrospective, observational study was performed to compare the efficacy of PGE1 and PLC, and to evaluate both the immediate results of an intensive, short-course rehabilitation program and the outcome at one year follow-up.


METHODS
Twenty-five patients with severe-moderate claudication were selected. All patients were subjected to an intensive, supervised exercise program for 4 weeks in combination with either PGE1 (10 patients) or PLC (15 patients). Drugs were infused i.v. before every exercise session: 60 microg PGE1 within 2 hours and 600 mg PLC within 10 minutes. Patients were trained with the same supervised tread-mill walking-exercise program. At the end of the rehabilitation period, patients were instructed to keep walking (advised home exercise). Initial claudication distance (ICD) and absolute claudication distance (ACD) were evaluated during a constant treadmill test (3 km/hour speed, 10% grade) at entry, after 4 weeks and at one year follow-up. A patient was considered as no-responder if his/her improvement in ACD was <33%.


RESULTS
A significant increase of both ICD and ACD was detected after both 4 weeks (+269% and +135%, respectively, in PGE1 group; +245% and +125%, respectively, in PLC group) and one year (+364% and +202%, respectively, in PGE1 group; +279% and +176%, respectively, in PLC group). No-responder patients after the intensive training period (2 in PGE1 group and 4 in PLC group) remained no-responders also at one year follow-up. Both PGE1 and PLC treatments were well tolerated. No serious drug-related side effect requiring interruption of the treatment was observed.


CONCLUSIONS
A short-course of intensive exercise treatment plus PLC or PGE1 may enhance walking ability. The result was confirmed at one year follow-up.
Rossini
Duccio
D
UO Cardiologia, Ospedale SS, Cosma e Damiano, AUSL 3 Regione Toscana, Pescia (PT), Italy. rossiniscuri@alice.it
Bulckaen
Massimo
M
Di Marco
Stefano
S
Giovannetti
Roberto
R
Giuntoli
Franco
F
Lacopetti
Luciana
L
Vergoni
William
W
D000368:Aged; D000527:Alprostadil / Q000627:therapeutic use*; D002331:Carnitine / Q000627:therapeutic use*; D005081:Exercise Therapy; D005260:Female; D006801:Humans; D007383:Intermittent Claudication / Q000534:rehabilitation*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014665:Vasodilator Agents / Q000627:therapeutic use*; D014803:Vitamin B Complex / Q000627:therapeutic use*
D014665:Vasodilator Agents; D014803:Vitamin B Complex; D000527:Alprostadil; D002331:Carnitine